MENLO PARK, Calif., May 20, 2014 -- Avalanche Biotechnologies, Inc., a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the appointment of Linda C. Bain as Chief...

Tarrytown, New York and Menlo Park, Calif., (May 5, 2014) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products...

– Proceeds will Further Strengthen Avalanche’s Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration –April 22, 2014MENLO PARK, Calif., April 22, 2014 -- Avalanche Biotechnologies, Inc, a leader in the development of...

Avalanche announced the completion of additional financing in a round consisting of both new and existing investors. Specific details of the financing, which included both preferred stock and convertible debt, were not disclosed. “Avalanche’s BioFactoryTM platform is...

June 12, 2013 In this week’s issue of Science Translational Medicine, UC Berkeley scientists report on vector-mediated delivery to the outer retina using proprietary technology licensed by Avalanche. The paper, which appeared in this week’s issue of Science...

October 1, 2012 Avalanche Biotechnologies, Inc. announced that it has been awarded two grants from the National Eye Institute to fund pre-clinical studies related to its novel AAV variant technology. The first grant, funded through the SBIR program with Dr. Thomas W....

Avalanche Biotechnologies, Inc., a leader in the area of long-term protein delivery for ocular diseases, and Lonza, a global leader in the field of biologics manufacturing, today announced a manufacturing collaboration focused on process development and scale-up...

Avalanche Biotechnologies, Inc. announced initiation of a collaboration with Lions Eye Institute, University of Western Australia to develop treatments for ocular diseases. The collaboration will initially focus on the development of AVA-101 for the treatment of wet...